These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36167466)

  • 1. Association of pharmacotherapy with the second hip fracture incidence in women: A retrospective analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Geriatr Gerontol Int; 2022 Nov; 22(11):930-937. PubMed ID: 36167466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    J Bone Miner Metab; 2023 Mar; 41(2):248-257. PubMed ID: 36853423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between pharmacotherapy and secondary vertebral fracture managed with a brace in a real-world setting: A nationwide database study in Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Geriatr Gerontol Int; 2024 Apr; 24(4):390-397. PubMed ID: 38475987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
    Byun SE; Kim H; Lee SY; Kim SM
    Osteoporos Int; 2024 May; 35(5):775-783. PubMed ID: 38240755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Arch Osteoporos; 2021 Sep; 16(1):131. PubMed ID: 34515872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
    Chen YJ; Kung PT; Chou WY; Tsai WC
    Osteoporos Int; 2020 Aug; 31(8):1555-1563. PubMed ID: 32221674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Arch Osteoporos; 2021 Sep; 16(1):130. PubMed ID: 34510296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for mortality after hip fracture surgery in Japan using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Nishimura Y; Inagaki Y; Noda T; Nishioka Y; Myojin T; Ogawa M; Kido A; Imamura T; Tanaka Y
    Arch Osteoporos; 2023 Jul; 18(1):91. PubMed ID: 37418095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims database.
    Mori T; Komiyama J; Fujii T; Sanuki M; Kume K; Kato G; Mori Y; Ueshima H; Matsui H; Tamiya N; Sugiyama T
    Arch Osteoporos; 2022 Apr; 17(1):61. PubMed ID: 35403938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiresorptive Drugs and the Risk of Femoral Shaft Fracture in Men and Women With Osteoporosis: A Cohort Study Using the National Database of Health Insurance Claims of Japan.
    Imai T; Hosoi T; Hagino H; Yamamoto T; Kuroda T; Watanabe H; Tanaka S
    J Epidemiol; 2023 Dec; 33(12):633-639. PubMed ID: 36567127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
    Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
    Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insufficient persistence of and adherence to osteoporosis pharmacotherapy in Japan.
    Nakatoh S; Fujimori K; Tamaki J; Okimoto N; Ogawa S; Iki M
    J Bone Miner Metab; 2021 May; 39(3):501-509. PubMed ID: 33403498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.